FormPour FDA Warning Letter: Letter 722215
Updated August 23, 2026
FormPour of Canton, Michigan received FDA warning letter 722215, dated March 31, 2026 and posted April 7, 2026, in a single-date batch of seven letters to research-peptide sellers. This index cites the letter through FDA's public warning-letters database, which retrieves it by recipient name.
The cart as evidence
The finding that distinguishes the March 2026 batch from earlier actions is structural rather than verbal: administration supplies listed for sale in the same cart as the compounds. In the letters, that pairing is itself cited as evidence of intended use. No product description had to say anything for the checkout's composition to enter the record — what a seller stocked next to the compounds spoke for the seller.
Therapeutic-effect descriptions
The batch's other recurring finding is the older one: product pages characterizing what a compound does in a human subject, published beside research-use-only labeling. The letters set the two side by side and resolved the contradiction in the agency's own words — despite the disclaimers, "evidence obtained from your website establishes that your products are intended to be drugs for human use." Both findings are documented at batch level across the seven letters; this index records FormPour as a recipient of the batch and does not itemize which findings its individual letter carries.
Record
| Recipient | FormPour |
|---|---|
| Location | Canton, MI |
| Letter number | 722215 |
| Letter date | March 31, 2026 |
| Posted to FDA index | April 7, 2026 |
| Batch | Seven letters, seven sellers, one date |
Where the letter is filed
No confirmed direct URL for letter 722215 has been captured by this index, so none appears on this page — a citation is either verified or it is the database search, never a constructed link. FDA's warning-letters index, linked under Sources, returns the letter by recipient name. This page records the letter's existence, number, date, and recipient; it makes no claim about anything FormPour did after receipt, because no such fact is in the verified record here.
Scale of the action
Seven letters signed on one date made March 31, 2026 the largest single-day warning-letter action against research-peptide sellers in this index's record. The previous multi-recipient action, dated December 10, 2024, named four sellers of GLP-1-class compounds. The two batches differ in method as well as size: the 2024 letters read product listings and, in one case, a post from a recipient's own social-media account, while the 2026 letters added the composition of the shopping cart to the evidentiary file. Trade coverage has reported more than one hundred FDA warning letters to peptide and research-use-only sellers since September 2025; the seven letters of this batch are the ones dated to a single day.
Context in the seven-letter action
FormPour is one of seven recipients dated March 31, 2026 — the others range from Florida to California, and the full roster with letter numbers and locations is tabulated at FDA warning letters of March 31, 2026. Each recipient, FormPour included, holds an entry in the vendor index.
Sources
- FDA Warning Letters index (retrieves the FormPour letter, 722215, by recipient name). fda.gov
- Policy Canary analysis of the March 31, 2026 batch. policycanary.io
- Partnership for Safe Medicines, PDF summary of the seven letters (April 7, 2026 posting). safemedicines.org
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.